MSS Clinical Trials

7 recruiting

MSS Trials at a Glance

20 actively recruiting trials for mss are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 11 trials, with the heaviest enrollment activity in Guangzhou, Beijing, and Los Angeles. Lead sponsors running mss studies include GV20 Therapeutics, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, and Beijing Hospital.

Treatments under study

About MSS Clinical Trials

Looking for clinical trials for MSS? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new MSS trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about MSS clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 20 trials

Recruiting
Phase 1

Clinical Study of MSH2-/- Tumor Cell Vaccines for Advanced pMMR Colorectal Cancer Patients

pMMR/MSS Advanced Colorectal Cancer
West China Hospital9 enrolled2 locationsNCT07510308
Recruiting
Phase 2

SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases

Colorectal CarcinomaOligometastasespMMR+2 more
First Affiliated Hospital of Zhejiang University51 enrolled1 locationNCT06850103
Recruiting
Phase 2

Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

Locally Advanced Rectal CarcinomapMMRMSS+1 more
Zhejiang University50 enrolled1 locationNCT05731726
Recruiting
Early Phase 1

Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms

Breast CancerAromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)Joint Pain
Philip Chang30 enrolled2 locationsNCT06123286
Recruiting
Phase 2

Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer (SPARK)

pMMR/MSS Locally Advanced Rectal Cancer
Dechang Diao86 enrolled1 locationNCT07005570
Recruiting
Phase 2

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
Stingray Therapeutics70 enrolled6 locationsNCT06589440
Recruiting
Phase 3

mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC

Colorectal Cancer (CRC)pMMR/MSS Adenocarcinoma of the Colon or Rectum
Jun Huang166 enrolled1 locationNCT06791512
Recruiting
Phase 1Phase 2

Study of GV20-0251 in Participants With Solid Tumor Malignancies

Solid Tumor CancerAdult Refractory CancerEndometrial Carcinoma (EC)+2 more
GV20 Therapeutics350 enrolled3 locationsNCT07070518
Recruiting
Phase 1

ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers

With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer
National University Hospital, Singapore16 enrolled2 locationsNCT06513624
Recruiting
Phase 1

Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors

Liver CancerEsophageal CancerGastric Cancer+9 more
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)18 enrolled1 locationNCT07001592
Recruiting
Phase 2

SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer

Rectal AdenocarcinomaHigh-Risk CancerMSS
Sixth Affiliated Hospital, Sun Yat-sen University49 enrolled1 locationNCT06908031
Recruiting
Phase 2

The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.

Advanced Colorectal Cancer in the Third-line Treatment and BeyondpMMR/MSS Advanced Colorectal Cancer
Shanghai Changzheng Hospital60 enrolled1 locationNCT06930118
Recruiting
Phase 1Phase 2

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

Solid Tumor, AdultCutaneous MelanomaRefractory Cancer+3 more
GV20 Therapeutics365 enrolled13 locationsNCT05669430
Recruiting
Not Applicable

Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer.

MSS Metastatic Colorectal Cancer
Ningbo Medical Center Lihuili Hospital30 enrolled1 locationNCT06613113
Recruiting

A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy

MSS Metastatic Colorectal CancersMSI Solid Tumors Refractory to PD1/PDL1 Antibody Monotherapy
Peking University Cancer Hospital & Institute50 enrolled1 locationNCT06549907
Recruiting
Phase 2

ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC

Metastatic Colorectal CancerRAS MutationMSS
Beijing Hospital60 enrolled1 locationNCT06321081
Recruiting
Phase 2

XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

CapecitabineTislelizumabBevacizumab+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences52 enrolled1 locationNCT05970302
Recruiting
Not Applicable

Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced,High-Risk,MSS Rectal Cancer

Rectal CancerLocally AdvancedMSS+1 more
Nanfang Hospital, Southern Medical University53 enrolled1 locationNCT05877573
Recruiting
Phase 2

XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer

Rectal CancerMSS
Cancer Institute and Hospital, Chinese Academy of Medical Sciences92 enrolled1 locationNCT05815303
Recruiting
Phase 4

CASSETTE - Clindamycin Adjunctive therapy for Severe Staphylococcus aurEus Treatment Evaluation – An investigator-initiated, multi-centre, parallel group, open labelled pilot randomised controlled trial

Severe methicillin-susceptible staphylococcus aureus (MSSA)Methicillin-Resistant Staphylococcus Aureus (MRSA)
Menzies School of Health Research60 enrolled11 locationsACTRN12617001416381